✦ LIBER ✦

Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis

✍ Scribed by Florence Wong; Pere Gines; Hugh Watson; Yves Horsmans; Paolo Angeli; Paul Gow; Pascal Minini; Mauro Bernardi

Book ID: 116652153
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 809 KB
Volume: 53
Category: Article
ISSN: 0168-8278
DOI: 10.1016/j.jhep.2010.02.036

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effects of satavaptan, a selective vasop

Effects of satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial

✍ Pere Ginès; Florence Wong; Hugh Watson; Slobodan Milutinovic; Luis Ruiz del Arbo 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 1 views

Hyponatremia in cirrhosis is associated with significant morbidity and mortality and complicates ascites management. Vasopressin receptor antagonists improve serum sodium concentration by increasing renal solute-free water excretion, but their effects on the management of ascites have not been asses

732 Effects of satavaptan (SR121463B), a

732 Effects of satavaptan (SR121463B), a selective vasopressin V2 receptor antagonist, on serum sodium concentration and ascites in patients with cirrhosis and hyponatraemia

✍ P. Gines; F. Wong; S. Milutinovic; L. Ruiz del Arbol; D. Olteanu 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 114 KB

Clinical trial: short-term effects of co

Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia – a randomized, double-blind, placebo-controlled study

✍ P. GINÈS; F. WONG; H. WATSON; R. TERG; R. BRUHA; J.-P. ZARSKI; F. DUDLEY; FOR TH 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 201 KB

102 EFFECTS OF SATAVAPTAN, AN ORAL VASOP

102 EFFECTS OF SATAVAPTAN, AN ORAL VASOPRESSIN V2 RECEPTOR ANTAGONIST, ON MANAGEMENT OF ASCITES AND MORBIDITY IN LIVER CIRRHOSIS IN A LONG-TERM, PLACEBO-CONTROLLED STUDY

✍ F. Wong; M. Bernardi; Y. Horsmans; Z. Cabrijan; H. Watson; P. Gines 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 66 KB

Acute hemodynamic effects of conivaptan,

Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure

✍ J.E. Udelson; W.B. Smith; G.H. Hendrix 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 33 KB

Effect of the V1a/V2-AVP receptor antago

Effect of the V1a/V2-AVP receptor antagonist, Conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites

✍ Guillermo Fernández-Varo; Josefa Ros; Pilar Cejudo-Martı́n; Carmen Cano; Vicente 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 329 KB